Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Gross Margin: 2009-2024

Historic Gross Margin for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to 63.38%.

  • Anika Therapeutics' Gross Margin fell 964.00% to 56.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 54.74%, marking a year-over-year decrease of 2007.00%. This contributed to the annual value of 63.38% for FY2024, which is 494.00% down from last year.
  • Per Anika Therapeutics' latest filing, its Gross Margin stood at 63.38% for FY2024, which was down 7.24% from 68.33% recorded in FY2023.
  • Anika Therapeutics' Gross Margin's 5-year high stood at 68.33% during FY2023, with a 5-year trough of 52.91% in FY2020.
  • Moreover, its 3-year median value for Gross Margin was 64.33% (2022), whereas its average is 65.34%.
  • In the last 5 years, Anika Therapeutics' Gross Margin tumbled by 2,201bps in 2020 and then surged by 821bps in 2022.
  • Anika Therapeutics' Gross Margin (Yearly) stood at 52.91% in 2020, then skyrocketed by 321bps to 56.12% in 2021, then surged by 821bps to 64.33% in 2022, then soared by 400bps to 68.33% in 2023, then crashed by 494bps to 63.38% in 2024.